Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Business

Hims & Hers Health says it will offer compounded GLP-1 injections

by admin May 23, 2024
May 23, 2024
Hims & Hers Health says it will offer compounded GLP-1 injections

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.

Shares of the company surged.

The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program.

Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available.

The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Even before it added compounded GLP-1s to its portfolio, Hims & Hers said in its fourth-quarter earnings report that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The company plans to offer updated guidance in its next earnings report.

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage.

GLP-1s mimic a hormone produced in the gut to tamp down a person’s appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. Food and Drug Administration requirements.

The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient’s needs.

In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.

Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able to access a consistent supply of the compounded medications.

Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.

“We have a certain degree of exclusivity with that facility that will guarantee our consumers consistent volume and supply,” he said.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Hims & Hers Health says it will offer compounded GLP-1 injections
next post
Top 5 ASX Technology Stocks

Related Posts

Tesla denies report that the EV maker is...

May 2, 2025

Rent up, groceries down: Inflation cooled slightly in...

May 17, 2024

DJT shares jump after Trump Media rolls out...

August 4, 2024

S&P 500 climbs for best day since early...

July 24, 2024

As their customers age, department stores chase younger...

May 21, 2024

Hunter Biden sues Fox News under New York’s...

July 2, 2024

Apple sued by shareholders who allege it overstated...

June 24, 2025

OpenAI introduces Operator to automate tasks like vacation...

January 24, 2025

GM to invest $625 million in joint venture...

October 18, 2024

Digital health companies pummeled by Wall Street in...

December 27, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Dem senator compares American founding principle to Iran’s theocracy: ‘Extremely troubling’

      September 5, 2025
    • China shows missiles, Trump shows muscle: Xi’s strategy can’t match US

      September 5, 2025
    • VP Vance curses out senators after heated Kennedy hearing: ‘Full of s— and everyone knows it’

      September 5, 2025
    • Trump stands by RFK Jr. after heated Senate hearing: ‘I like the fact that he’s different’

      September 5, 2025
    • Whatever happened to: The Qatar Air Force One jet

      September 5, 2025

    Categories

    • Business (1,101)
    • Investing (2,978)
    • Politics (3,629)
    • Stocks (1,155)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved